Biotech Stocks on Investors' Radar -- Eleven Biotherapeutics, CytRx, Celldex Therapeutics, and ACADIA Pharma

Sep 14, 2016, 09:19 ET from Chelmsford Park SA

NEW YORK, September 14, 2016 /PRNewswire/ -- has uncovered research reports on the following Biotech companies: Eleven Biotherapeutics Inc. (NASDAQ: EBIO), CytRx Corp. (NASDAQ: CYTR), Celldex Therapeutics Inc. (NASDAQ: CLDX), and ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD). On Monday, September 13, 2016, the iShares NASDAQ Biotechnology ETF (IBB) rose 3%, which was its best day since late June. The IBB, however, is still down 19% in the past year. Learn more about these stocks by downloading their comprehensive and free reports at:

Eleven Biotherapeutics  

At the close on Tuesday, shares in Cambridge, Massachusetts-based Eleven Biotherapeutics Inc. saw a drop of 3.66%, ending the day at $4.21. The stock recorded a trading volume of 348,906 shares. The Company's shares have surged 85.46% in the previous three months and 39.87% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 9.97% and 117.38%, respectively. Moreover, shares of Eleven Biotherapeutics, which engages in the discovery and development of protein therapeutics to treat eye diseases primarily in the US, have a Relative Strength Index (RSI) of 46.84.

On August 16th, 2016, Eleven Biotherapeutics (Eleven) announced the effectiveness of the exclusive licensing deal with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (Roche). Eleven has granted Roche an exclusive, worldwide license to develop and commercialize EBI-031 and all other IL-6 antagonist antibody technology owned by Eleven. EBI-031 is currently in development for the treatment of ocular diseases. Eleven is entitled to receive $30 million in payments from Roche, including a $7.5 million upfront payment in connection with the effectiveness of the license agreement, and a $22.5 million milestone payment based on the Investigational New Drug application (IND) for EBI-031 becoming effective. Under the terms of the agreement, Eleven could receive up to an additional $240 million upon the achievement of certain future regulatory, development and commercialization milestones. EBIO complete research report is just a click away and free at:


Shares in Los Angeles, California headquartered CytRx Corp. ended the day 3.18% lower at $0.57 and with a total trading volume of 1.37 million shares. The stock is trading below its 50-day moving average by 30.62%. Shares of the Company, which operates as a biopharmaceutical research and development company specializing in oncology, have an RSI of 43.82.

On September 7th, 2016, CytRx announced that it has reached its enrollment target of 132 patients for the company's global Phase 2b clinical trial of aldoxorubicin in patients with previously treated small cell lung cancer (SCLC). The Phase 2b study is a randomized, comparative trial being conducted at 41 sites in the US, Hungary and Spain.  Because of the unmet medical need for patients with second-line SCLC, if the global Phase 2b clinical trial results are positive, CytRx intends to meet with the US FDA to discuss the regulatory pathway for the submission of a New Drug Application for aldoxorubicin in this patient population. The complimentary report on CYTR can be downloaded at:

Celldex Therapeutics  

On Tuesday, shares in Hampton, New Jersey headquartered Celldex Therapeutics Inc. finished 3.50% lower at $3.58 and with a total trading volume of 1.89 million shares. The stock is trading below its 50-day moving average by 15.80%. Shares of the Company, which develops, manufactures, and commercializes novel therapeutics for human health care in the US, have an RSI of 41.51.

On August 11th, 2016, Celldex Therapeutics announced that the Company has promoted Elizabeth Crowley to the newly created position of Senior Vice President, Chief Product Development Officer. Ms. Crowley was previously Senior Vice President of Product Development of Celldex and brings almost 25 years of industry experience where she was responsible for leading the execution of multiple successful drug development programs. Sign up for your complimentary research report on CLDX at:

ACADIA Pharma  

San Diego, California headquartered ACADIA Pharmaceuticals Inc.'s shares recorded a trading volume of 1.18 million shares at the end of yesterday's session and closed the day at $32.07, dropping 1.23%. The stock has advanced 2.23% in the last one month. The Company's shares are trading above their 200-day moving average by 5.99%. Additionally, shares of ACADIA Pharmaceuticals, which focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders, have an RSI at 47.62.

On August 23rd, 2016, ACADIA announced the appointment of Todd S. Young as Executive Vice President, Chief Financial Officer, effective on August 22nd, 2016. Mr. Young reports to Steve Davis, ACADIA's President and Chief Executive Officer. Mr. Young joins ACADIA from Baxalta Inc., where he served as Senior Vice President and Treasurer, and played an integral role as a business leader and in creating the initial capital structure of Baxalta. Get free access to your research report on ACAD at:


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number:  +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA